Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding

JCO Precis Oncol. 2023 Jan:7:e2200340. doi: 10.1200/PO.22.00340.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bile Duct Neoplasms* / drug therapy
  • Bile Duct Neoplasms* / genetics
  • Bile Duct Neoplasms* / pathology
  • Bile Ducts, Intrahepatic / pathology
  • Cholangiocarcinoma* / drug therapy
  • Cholangiocarcinoma* / genetics
  • Humans
  • Ligands
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics

Substances

  • pemigatinib
  • Ligands
  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2